Eric K. Rowinsky - 17 Jun 2025 Form 4 Insider Report for BIOGEN INC. (BIIB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Jun 2025, 16:44:15 UTC
Prior SEC filing
27 May 2025
Next SEC filing
26 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Wendell Taylor, Attorney in Fact for Eric K. Rowinsky

Key filing fact

Eric K. Rowinsky filed Form 4 for BIOGEN INC. (BIIB) on 18 Jun 2025.

Key facts

  • This page summarizes Eric K. Rowinsky's Form 4 filing for BIOGEN INC. (BIIB).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 18 Jun 2025, 16:44.

Change

  • Previous filing in this sequence was filed on 27 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001318886 Primary reporting owner

Rowinsky Eric K

Relationship
Director
Address
BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE
Signature
/s/ Wendell Taylor, Attorney in Fact for Eric K. Rowinsky
Signature date
18 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIIB transaction

Common Stock

Award

Transaction value
$0
Shares
+2,370
Change %
+11%
Price
$0.000000
Shares after
24,339
Date
17 Jun 2025
Ownership
Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .